Ramírez CE, Velázquez SG, González RE, Cicero SR

Language: Spanish
References: 15
Page: 86-90
PDF size: 47.00 Kb.

ABSTRACT

Study objectives: Evaluate the clinical efficacy of two doses of amoxicillin (500 mg)–sulbactam (500 mg), in the treatment of exacerbations of chronic bronchitis. Design: Open trial of consecutive cases. Setting: External consultation department of the pneumology service in an open general hospital. Material and methods: Two groups of patients were studied, I of 20 cases with amoxicillin-sulbactam every eight hours and II of 19 cases every 12 hours. In all cases bacteriologic study of the sputum was done. The clinical response to the medication. Results: Pathogenic microorganisms were isolated in 29 cases, 10 were negative. The clinical response was evaluated in 36 of 39 patients being satisfactory in 94.1% of the Group I and 84.2% of the group II, with an improvement of dysnea, cough and the sputum. Bacteriologic eradication in the positive cases was obtained in 11/14, group I and 10/15, group II. Tolerance to the medication was better with the administration every 12 h. It is important to mention that we do not find Haemophilus influenzae neither Streptococcus pneumoniae as pathogen agents. We find meanly Staphylococcus aureus and some bacterias commonly founded in faecalism. We explain this because many patients live in areas with many sanitary problems. Conclusion: Amoxicillin-sulbactam administration for exacerbations of chronic bronchitis was useful, there were no differences in efficacy between the two schedules of administration every eight hours and every 12 h.

REFERENCES

1. Sansores RH, Pérez-Padilla R. Enfermedad pulmonar obstructiva crónica. Un problema Mundial. Un enfoque en México. México: Editorial Piensa, 1997: 36-42.

2. Barter CE, Campell AH. Relationship of constitutional factors and cigarette smoking to disease in I. Second forced expiratory volume. Am Rev Respir Dis 1976; 113: 305-314.

3. American Thoracic Society Statement. “Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S78-S121.

4. Burrows B, Knudson RJ, Camilli AE et al. The “horse-racing effect” and prediciting decline in force expiratory volume in one second from screening spirometry. Am Rev Resp Dis 1987; 135: 788-789.

5. Ramírez CE, González RE, Cicero SR, Olvera CR, Ferreira E. Enfermedad pulmonar crónica -EPOC- en dos Hospitales de la ciudad de México. Rev Inst Enf Resp Mex 1995; 8: 16-20.

6. Derenne JP, Fleury B, Pariente R. Acute respiratory failure of chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138: 1006.

7. Gross NJ. COPD: A disease of reversible air-flow obstruction. Am Rev Resp Dis 1986; 133: 725.

8. Philippon A, Riou MJY, Guibourdenche M et al. Detection and distribution of Branhamella catarrhalis b-lactamasas. Drugs 1986; 31 (suppl 3): 64-69.

9. Foulds G, Stankewich JP. Marshall DC et al. Pharmacokinetic of sulbactam in inhibition of Branhamella catarrhalis b-lactamasas. Drugs humans. Antimicrob Agents Chemot 1983; 31 (suppl 3): 64. 23: 692-699.

10. D’ Andrea EM, Guaycocheas CJM. Eficacia de amoxicilina-sulbactam en cepas productoras de b-lactamasas. 2o Congreso Panamericano de Infectología y 1er Congreso de la Sociedad Argentina de Infectología. 1984, Buenos Aires (Argentina).

11. Williams JD, Moosdeen F. Antibiotic resistance in Haemophilus influenzae: Epidemiology, mechanisms and therapeutic possibilities. Rev Infectious Dis 1986; 8 (suppl 5): S 555-561.

12. McLeod DT, Ahmad F, Croughan MJ et al. Bronchopulmonary infection response. Drugs 1986; 31 (suppl 3): 109-112.

13. Foulds G, Stankewich JP, Marshall D et al. Pharmacokinetic of sulbactam in humans. Antimicrob Agents Chemot 1983; 23 (5): 692-699.

14. Giurno H. Amoxicilina + sulbactama, en infecciones bacterianas agudas comunes en la práctica médica. Comahue Médico 1988; 18 (97): 17-19.

15. Foulds G. Pharmacokinetics of sulbactam/ampicilin in humans: A review. Rev Inf Disease 1986; 8 (suppl 5): S505-S511.